Thyroid status as prognostic marker in oncology

Abstract


In spite of advances in the treatment of malignant tumors of various localizations, in general, the survival rate for a variety of clinical entities remains unsatisfactory. There is no doubt that the predictive value of clinical stage of disease is very valuable. However in each particular case the correlation between the stage of disease and its outcome is rather probable than absolute. The current laboratory and pathological methods of risk assessment of course and recurrence of tumor in patients suffered from malignancies are not always sufficient, adequate and in most cases are able to ascertain a certain degree of risk without dosage adjustment possibilities. In the middle of the last century hypothyroidism was recognized as a risk factor for the development of certain malignancies, such as breast cancer, that has for several decades thesis conclusive clinical oncology. However at the turn of the century advances in molecular biology have called into question many of the existing dogma of experimental and clinical oncology. The review presents data about nongenomic properties of thyroid hormones (TH). Extracellular domains of integrin αVβ3, which is cell adhesion protein, are entrance for nongenomic way of TH. Binding of TH to αVβ3 results in activation of mitogen-activated protein kinase (fosfatidil-inositol-3-kinase). The finale effects of TH nongenomic action are cell proliferation, angiogenesis, migration of cells and elevated expression of tissue specific inflammatory genes. The clinical studies presented here trace pattern between increase in response to treatment and increase in survival of cancer patients with hypothyroid condition.

Full Text

Restricted Access

About the authors

Ruslan Ivanovich Glushakov

State Pediatric Medical University

Email: glushakovruslan@gmail.com
MD, PhD, Associate Professor, Department of pharmacology

Olga Valerievna Vlaseva

Russian Medicomilitary Academy

Email: olgavlaseva@yandex.ru
Resident doctor. Department of oncology

Ivan Viktorovich Sobolev

St. Petersburg Clinical Research Center of Specialized Types of Medical Care

Email: sobol548@inbox.ru
Oncologist, Department of gynecology

Sergei Nikolaevich Proshin

State Pediatric Medical University

Email: psnjsn@rambler.ru
MD, PhD, Dr Med Sci, Professor, Head of the Department of Pharmacology

Natalya Igorevna Tapil’skaya

State Pediatric Medical University

Email: tapnatalia@yandex.ru
MD, PhD, Dr Med Sci, Professor, Department of Obstetrics and Gynecology

References

  1. Aghajanova L., Lindeberg M., Carlson I. B. Receptors for thyroid-stimulating hormone and thyroid hormones in human ovarian tissue. Reprod. Biomed. Online. 2009; 18 (3): 337-347.
  2. Ashur-Fabian O., Blumenthal D. T., Bakon M. Long-term response in high-grade optic glioma treated with medically induced hypothyroidism and carboplatin: a case report and review of the literature. Anticancer Drugs. 2013; 24 (3): 315-323.
  3. Balkwill F., Charles K. A., Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005; 7: 211-217.
  4. Billon N., Terrinoni A., Jolicoeur C. Roles for p53 and p73 during oligodendrocyte development. Development. 2004; 131: 1211-1220.
  5. Brown R. L. Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management. Target Oncol. 2011; 6 (4): 217-226.
  6. Cao X., Kambe F., Moeller L. C. Thyroid hormone induces rapid activation of Akt/protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts. Mol. Endocrinol. 2005; 19 (1): 102-112.
  7. Carvalho A. F., Dimellis D., Gonda X. Rapid cycling in bipolar disorder: a systematic review. J. Clin. Psychiatry. 2014; 75 (6): 578-586.
  8. Cohen K., Ellis M., Khoury S. Thyroid hormone is a MAPK-dependent growth factor for human myeloma cells acting via αvβ3 integrin. Mol. Cancer Res. 2011; 9 (10): 1385-1394.
  9. Crile G. Jr. The endocrine dependency of certain thyroid cancers and the danger that hypothyroidism may stimulate their growth. Cancer. 1957; 10 (6): 1119-1137.
  10. Davis F. B., Tang H. Y., Shih A. Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells. Cancer Res. 2006; 66 (14): 7270-7275.
  11. Davis F. B., Mousa S. A., O’Connor L. Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ. Res. 2004; 94 (11): 1500-1506.
  12. Davis P. J., Lin H. Y., Tang H. Y. Adjunctive input to the nuclear thyroid hormone receptor from the cell surface receptor for the hormone. Thyroid. 2013; 23 (12): 1503-1509.
  13. Demartini B., Ranieri R., Masu A. Depressive symptoms and major depressive disorder in patients affected by subclinical hypothyroidism: a cross-sectional study. J. Nerv. Ment. Dis. 2014; 202 (8): 603-607.
  14. Faber J., Selmer C. Cardiovascular disease and thyroid function. Front. Horm. Res. 2014; 43: 45-56.
  15. Farwell A. P., Dubord-Tomasetti S. A., Pietrzykowski A. Z., Leonard J. L. Regulation of cerebellar neuronal migration and neurite outgrowth by thyroxine and 3,3',5'-triiodothyronine. Brain Res. Dev. Brain Res. 2005; 154 (11): 121-135.
  16. Hercbergs A. A., Suh J. H., Lee S. Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study. Anticancer Res. 2003; 23 (1B): 617-626.
  17. Huang S. A. Physiology and pathophysiology of type 3 deiodinase in humans. Thyroid. 2005; 15 (8): 875-881.
  18. Humphrey L. J., Swerdlow M. The relationship of breast disease to thyroid disease. Cancer. 1964; 17: 1170-1173.
  19. Linetsky E., Hercbergs A. A., Dotan S. Time to tumor progression (TTP) and quality of life (QOL) following propylthiouracil induction of chemical hypothyroidism in failed malignant gliomas. Abstracts from the World Federation of Neuro-Oncology Second Quadrennial Meeting and the Sixth Meeting of the European Association for Neuro-Oncology: Edinburgh, U. K. 2005.
  20. Lodish M. B., Stratakis C. A. Endocrine side effects of broad-acting kinase inhibitors. Endocr. Relat. Cancer. 2010; 17 (3): 233-244.
  21. Moeller L. C., Dumitrescu A. M., Walker R. L. Thyroid hormone responsive genes in cultured human fibroblasts. J. Clin. Endocrinol. Metab. 2005; 90 (2): 936-943.
  22. Nelson M., Hercbergs A., Rybicki L., Strome M. Association between development of hypothyroidism and improved survival in patients with head and neck cancer. Arch. Otolaryngol. Head Neck Surg. 2006; 132 (10): 1041-1046.
  23. Rae M. T., Gubbay O., Kostogiannou A. Thyroid hormone signaling in human ovarian surface epithelial cells. J. Clin. Endocrinol. Metab. 2007; 92 (1): 322-327.
  24. Reid I., Sharpe I., McDevitt J. Thyroid dysfunction can predict response to immunotherapy with interleukin-2 and interferon-2 alpha. Br. J. Cancer. 1991; 64 (5): 915-918.
  25. Riesenbeck L. M., Bierer S., Hoffmeister I. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. World J. Urol. 2011; 29 (6): 807-813.
  26. Russfield A. B. Histology of the human hypophysis in thyroid disease-hypothyroidism, hyperthyroidism, and cancer. J. Clin. Endocrinol. Metab. 1955; 15 (11): 1393-1408.
  27. Sabatier R., Eymard J. C., Walz J. Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma? Ann. Oncol. 2012; 23 (3): 714-721.
  28. Schmidinger M., Vogl U. M., Bojic M. Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer. 2011; 117 (3): 534-544.
  29. Schwartz M. A. Integrin signaling revisited. Trends Cell Biol. 2001; 11: 466-470.
  30. Shih C., Chen S., Yen C. Thyroid hormone receptor-dependent transcriptional regulation of fibrinogen and coagulation proteins. Endocrinology. 2004; 145: 2804-2814.
  31. Siegrist-Kaiser C. A., Juge-Aubry C., Tranter M. P. Thyroxine-dependent modulation of actin polymerization in cultured astrocytes. A novel extranuclear action of thyroid hormone. J. Biol. Chem. 1990; 265: 5296-5302.
  32. Smith T. G., Roblins P. A., Ratelife P. J. The human side of hypoxia-inducible factor. Brit. J. Haemot. 2008; 141: 325-334.
  33. Tang H. Y., Lin H. Y., Zhang S. Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor. Endocrinology. 2004; 145: 3265-3272.
  34. Viguerie N., Millet L., Avizou S. Regulation of human adipocyte gene expression by thyroid hormone. J. Clin. Endocrinol. Metab. 2002; 87: 630-634.
  35. Wang X., Page-McCaw A. A matrix metalloproteinase mediates long-distance attenuation of stem cell proliferation. J. Cell Biol. 2014; 206 (7): 923-936.
  36. Weijl N. I., Van der Harst D., Brand A. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J. Clin. Oncol. 1993; 11 (7): 1376-1383.
  37. Wolter P., Stefan C., Decallonne B. Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC). ASCO Meeting Abstracts. 2008.

Statistics

Views

Abstract - 1251

PDF (Russian) - 347

Cited-By


PlumX


Copyright (c) 2015 Glushakov R.I., Vlaseva O.V., Sobolev I.V., Proshin S.N., Tapil’skaya N.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies